Latest flutamide Stories
Men taking androgen deprivation therapy (ADT) for prostate cancer may have an increased risk of colorectal cancer.
In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.
A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.
Hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, but U.S. researchers suggest why.
Degarelix avoids initial hormone surge seen in other drugsMore than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU International.They also experienced much greater falls in their prostate-specific antigen (PSA) levels at 14 and 28 days than men taking leuprolide.Researchers from Canada, the USA, France, Denmark and the Netherlands...
WILMINGTON, Del., Sept.
Some drugs given to men to help treat prostate cancer may actually spur some cancer cells to grow, U.S. researchers said.
SCIENTISTS are hailing a new drug to treat aggressive prostate cancer as potentially the most significant advance in the field for 70 years. Abiraterone could treat up to 80% of patients with a deadly form of the disease resistant to currently available chemotherapy, they said.
Ambrilia Biopharma has initiated a Phase I/II clinical development program of its proprietary, novel three-month formulation of goserelin, in hormone-sensitive prostate cancer patients.
- A political dynamiter.